Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Van den Heuvel-Eibrink group

Van den Heuvel-Eibrink’s research includes translational research projects in pediatric oncology, with a special focus on 1) innovation for pediatric renal tumors, 2) (genetic) determinants of toxicity during and after childhood cancer.

Group leader: Prof.dr. M.M. van den Heuvel-Eibrink
Phone +31 (0) 88 97 272 72
Renal tumors:

Clinical (survival and toxicity) outcome determinants research, diagnostic innovation(radiology, diagnostic discriminating molecular biomarker identification), oncogenetic characterization research (genotype-phenotype correlation and identification of renal tumor-susceptibility), molecular research (NGS, organoids, and target identification, compound screens), innovative treatment development (chemo-, immunotherapy, radiotherapy and surgical treatment), in Wilms tumors, as well as rare non-Wilms tumors. 

"Our group is dedicated to translational research with a special focus on renal tumors and the (genetic) variation of early and late toxicity of childhood cancer through international collaboration." Prof.dr. Marry van den Heuvel - Eibrink - Group leader



Quality of cure and toxicity research:

We focus on the identification of (genetic) determinants of early and late toxicity of childhood cancer, especially endocrine sequelae, and ototoxicity. This includes the establishment of the prospective longitudinal Princess Máxima Center cohort CTCAE based toxicity registry, the “Continuous Registration of direct tOxicity by prospective dataWare housiNg (the Princess Máxima Center-CROWN registry)”, and its accompanying research projects, with a special focus on genetic variation. This program includes the development of international guidelines for surveillance and intervention studies.


Van den Heuvel-Eibrink group